Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade-Reference-Cited by-同舟云学术

Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade

Published:2020-07-23 Issue:14 Volume:5 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Lee Bo Ryeong,Chae Sehyun,Moon Jihyun,Kim Myeong Joon,Lee Hankyu,Ko Hyuk Wan^ORCID,Cho Byoung Chul^ORCID,Shim Hyo Sup^ORCID,Hwang Daehee,Kim Hye Ryun,Ha Sang-Jun^ORCID

Funder

the Korea government (MSIT), the Institute for Basic Science, Ministry of Food and Drug Safety

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/128633/files/pdf

Reference50 articles.

1. Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

3. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

4. Predictive biomarkers for checkpoint inhibitor-based immunotherapy

5. PD-1/PD-L1 inhibitors

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12);OncoImmunology;2024-06-24

2. CD155 Expression in Early-Stage Lung Adenocarcinoma;The Annals of Thoracic Surgery;2024-06

3. Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases;Acta Dermato-Venereologica;2024-02-07

4. ADAR-mediated RNA editing regulates PVR immune checkpoint in colorectal cancer;Biochemical and Biophysical Research Communications;2024-02

5. MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma;Cancer Science;2023-08-10